ArticleThe Lancet. Global health2026
Prevalence, characteristics, and clinical course of mpox-related ophthalmic disease (MBOTE-EYE): a prospective cohort study in South Kivu, Democratic Republic of the Congo.
Article in The Lancet. Global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Patient with longstanding mpox keratitis successfully treated with topical Cidofovir 0.5% eye drops: a case report.BMC ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
Abstract
backgroundSystematic longitudinal ophthalmologist-led assessment of mpox-related ophthalmic disease (MPOXROD) is rarely reported. We aimed to characterise the prevalence and clinical course of MPOXROD under supportive management during a clade Ib outbreak.
methodsMBOTE-EYE was a substudy nested within a prospective cohort in South Kivu, Democratic Republic of the Congo. All hospitalised patients with PCR-confirmed mpox (within the last 48 h) were eligible. Participants underwent ophthalmological examination at enrolment, discharge, and days 29 and 59. Conjunctival swabs were collected for monkeypox virus PCR. Risk factors for MPOXROD were assessed using mixed-effects Poisson regression.
findingsBetween Oct 28, 2024, and June 30, 2025, 310 participants were enrolled (median age 14·0 years [IQR 2·5-25·0]; 166 [54%] female). At enrolment, conjunctival disease was present in 112 (36% [95% CI 31-42]) participants, corneal disease in 24 (8% [5-11]), and anterior uveitis in two (1% [0-2]). Overall, 134 (43% [38-49]) participants developed MPOXROD during follow-up, most often bilaterally. Blindness following ulcerative keratitis occurred in two (1% [0-3]) of 224 participants. Periorbital lesions (adjusted risk ratio [aRR] 3·65 [95% CI 2·42-5·49]) and severe acute malnutrition (aRR 3·16 [1·22-8·22]) were associated with MPOXROD. PCR was done among 89 patients and cycle threshold values below 25 occurred exclusively during active MPOXROD.
interpretationOphthalmic involvement in clade Ib mpox is common and frequently bilateral, with a substantial burden of keratitis and risk of vision loss. Systematic eye examinations should be integrated into mpox care, and targeted ophthalmic therapies should be developed.
fundingCanadian Institutes of Health Research and the International Development Research Centre, the European & Developing Countries Clinical Trials Partnership, and the Belgian Directorate-General for Development Cooperation and Humanitarian Aid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.